Cancer Res Treat.  2013 Dec;45(4):349-353.

Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease

• Kim HC
• Lee JS
• Kim SH
• So HS
• Woo CY
• Lee JL

Abstract

Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.

Keyword

Von Hippel-Lindau disease; Neoplasm metastasis; Renal cell carcinoma; Sunitinib

MeSH Terms

Carcinoma, Renal Cell*
Central Nervous System
Humans
Neoplasm Metastasis
Prognosis
Protein-Tyrosine Kinases
von Hippel-Lindau Disease*
Protein-Tyrosine Kinases

Figure

• 

  Fig. 1 Response of metastatic renal cell carcinoma developed in patients in Von Hippel-Lindau disease to sunitinib. Selected target lesions showed favorable response.

• 

  Fig. 2 No change in size of cerebellar hemangioblastoma and pancreatic cysts during sunitinib treatment.

Reference

1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003; 361:2059–2067. PMID: 12814730.

2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335:865–875. PMID: 8778606.

3. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338:1272–1278. PMID: 9562581.

4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356:115–124. PMID: 17215529.

5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271–2281. PMID: 17538086.

6. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28:2144–2150. PMID: 20368553.

7. Friedrich CA. Von Hippel-Lindau syndrome: a pleomorphic condition. Cancer. 1999; 86(11 Suppl):2478–2482. PMID: 10630173.

8. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011; 22:2661–2666. PMID: 22105611.

9. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010; 40:980–985. PMID: 20457723.

10. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378:1931–1939. PMID: 22056247.

11. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010; 116:5400–5406. PMID: 21105118.

12. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003; 98:82–94. PMID: 12546356.

13. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000; 119:1087–1095. PMID: 11040195.